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We present a formalism for using functional imaging both to derive patient-specific 
radiobiological properties and consequently to prescribe optimal non-uniform radiotherapy 
dose distributions. The ability to quantitatively assess the response to an initial course of 
radiotherapy would allow the derivation of radiobiological parameters for individual patients. 
Both an iterative optimization and an analytical approach to this problem were investigated 
and illustrated by application to the linear-quadratic model of cell killing using simulated 
parametric data for a modelled tumor. Potential gains in local control were assessed by 
comparing uniform dose distributions with optimized dose distributions of equal integral 
dose. The effect on local prescribed dose of variations in effective radiosensitivity, tumor 
burden and proliferation rate was investigated, with results suggesting that dose variations 
would be significant but clinically achievable. The sensitivity of derived parameters to image 
noise and the effect of varying the initial fractionation and imaging schedule were assessed. 
The analytical approach proved remarkably robust, with 10% image noise resulting in dose 
errors of approximately 1% for a clinically relevant set of parameters. Potential benefits were 
demonstrated by using this formalism to prescribe non-uniform dose distributions for model 
tumors using a range of literature-derived parameters. The redistribution of dose improved 
tumor control probability by factors between 1.03 and 4.27 for a range of model tumors.  
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I. INTRODUCTION 
The primary aim of treatment planning for radical radiotherapy has traditionally been 
to deliver a uniform high dose to a tumor in order to eradicate all the tumor cells. This aim is 
formalized in guidance on radiotherapy planning from the International Commission on 
Radiation Units and Measurements (ICRU)1,2 and is supported both by years of clinical 
experience and by mathematical modelling of the radiobiology of tumors.3 This approach 
assumes tumors to be uniform, homogeneous entities, a perfectly sensible approximation in 
the absence of reliable techniques for determining the precise location and the anatomical and 
functional structure of the tumor, and for calculating and delivering complex dose 
distributions. However, emerging medical imaging techniques are giving us more information 
than ever before on structural, biological and chemical variations within tumors.4-8 At the 
same time, intensity-modulated radiotherapy (IMRT) techniques give us unprecedented 
control over the spatial deposition of dose within a patient.9,10 There has therefore been much 
recent discussion regarding how best to incorporate information on tumor inhomogeneities 
into the treatment planning process in order to produce a genuinely optimal non-uniform dose 
distribution.11-20 
Most approaches to this problem begin with a mathematical model describing the 
response of the tumor to irradiation, and propose using imaging techniques to estimate spatial 
variations in the key parameters of this model (usually tumor burden and radiosensitivity). 
However, the values used are often baseline values of radiosensitivity parameters that come 
from in-vitro studies,21-24 or at best clinical studies giving a population average.25-27 There are 
therefore large uncertainties in the values of these parameters for a given individual patient, 
causing errors in estimating the absolute effect of varying dose distributions. However, with 
the development of novel imaging agents and improvements in quantitative functional 
imaging, it may soon be possible to quantify tumour response by imaging before and after an 
initial course of treatment.8,28 Patient-specific radiobiological parameters could then be 
derived from this assessment and used to plan a further course of treatment. The aim of this 
work is to investigate possible strategies for using functional imaging both to derive patient-
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specific radiobiological parameters and to design optimal dose distributions based on these 
parameters.  
II. METHODS 
II.A. Patient-Specific Optimization 
We begin with a multi-parameter model describing the response of a tumor to 
treatment. In order to accurately predict the response of a particular tumor to a given course of 
treatment, we must have accurate knowledge of the value of each significant parameter. Some 
parameters, notably those relating to tumor burden and chemical environment, may be 
assessed by acquiring appropriate images of the tumor prior to treatment. However, 
parameters relating to the dynamic response of the tumor cannot be ascertained in this manner 
and a different approach is needed, the most common being to use the results of in-vitro 
studies or analyses of clinical outcome as an estimate. However, there is evidence that there 
may be significant variations in radiosensitivity within a population of otherwise similar 
tumors.29,30 In order for a model to produce useful predictions, it may therefore be necessary 
to determine patient-specific values for these parameters. We consider two approaches to this 
problem: the first is to acquire images of the tumor before and after a single phase of 
treatment, and numerically optimize the set of unknown parameters such that the response 
predicted by the model best matches the observed response; the second is to determine how 
much information is needed in order to derive the unique set of unknown parameters 
analytically and to design a sequence of treatment phases and image acquisitions to acquire 
this information. Here we apply both of these techniques to a specific radiobiological model 
and assess the feasibility, accuracy and robustness of each.  
II.B. Radiobiological Model 
We follow the approach of Webb and Nahum31 by considering a tumor divided into n 
equal-sized voxels, each of volume v. If the radiation response is described by the linear-
quadratic model, the surviving fraction of tumor cells following irradiation to dose D in f 
fractions is given by: 
Prescribing radiotherapy dose distributions using patient-specific information 
 4






∆+





−−= tf
DDSF γβα
2
exp        (1) 
where α and β are the linear and quadratic parameters of cell kill, γ is the repopulation rate 
and ∆t the overall treatment time. The tumor control probability (TCP) is found by assuming 
Poisson statistics and calculating the probability of there being no viable tumor cells 
remaining. The probability of killing all tumor cells within a single voxel i is given by:  
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Where ρi is the clonogenic cell density in voxel i and Di the dose delivered to voxel i. The 
overall TCP for the whole tumor is then the product of the TCPs for all voxels: 
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In order to choose the dose distribution (i.e. the set of Di values for a chosen f  and ∆t) which 
will give the best overall TCP (subject to any dose delivery constraints), we need to know the 
spatial distribution of ρ, α, β and γ. At this point we will assume that the linear and quadratic 
parameters have some intrinsic value for a given patient, which is then modulated by spatial 
variations in chemical or biological properties within the tumor. The dominant modulating 
factor is likely to be oxygenation, since hypoxia is known to dramatically reduce 
radiosensitivity.32-34 We therefore require both a means of determining the intrinsic values of 
α, β and γ, and techniques for quantitatively imaging the distribution of clonogenic cell 
density and of hypoxia. Recent advances in positron emission tomography (PET) and 
magnetic resonance imaging and spectroscopy, particularly the development of new 
techniques for imaging tumor cell metabolism35,36 and hypoxia,37-40 show progress towards 
fulfilling the imaging requirements. Here we present methods for quantifying the intrinsic 
radiobiological parameters for a specific patient.  
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II.C. Deriving Patient-Specific Radiobiological Parameters from Image Data 
II.C.1. Method I: Numerical Optimization  
Given images of the clonogen density distribution before a single initial treatment 
phase, a good estimate of spatial variations in oxygenation during treatment and knowledge of 
the delivered dose, an initial estimate of α, β and γ values can be used to generate a prediction 
of the post-treatment clonogen map. If a post-treatment clonogen density image is also 
acquired, the observed and predicted data can be compared and the parameter values 
iteratively adjusted to minimize the difference.  
Within a given voxel i, phase 1 delivers total dose Di[1] in f[1] fractions over a total 
time ∆t[1]. The effective linear and quadratic terms of radiosensitivity will be the intrinsic 
radiosensitivity terms multiplied by factors Ai [1] and Bi [1] respectively, such that 
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where Ai [1] and Bi [1] are functions of the oxygenation. Note that we make no assumptions at 
this stage about the precise form of the relationship between oxygenation and 
radiosensitivity,41,42 we simply assume that Ai [1] and Bi [1] can be adequately estimated from 
the hypoxia images. If the number of clonogens present in the voxel prior to treatment is Ni [0], 
then following phase 1 the number of surviving clonogens is given by: 
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A suitable objective function (OF) for the optimization process would then be given by: 
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where the sum is taken over all tumor voxels. Minimizing the value of this function should 
give the best estimate of α, β and γ.  
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II.C.2. Method II: Analytical Derivation 
If ρ can be imaged directly, we will then require sufficient information to derive 
analytically the remaining independent parameters, in this case α, β and γ. If clonogen density 
is imaged before treatment, then again after each of three test phases of treatment, the linear-
quadratic equations can be solved analytically to give effective values of α, β and γ within 
each tumor voxel. If spatial variations in oxygenation are also imaged for each treatment 
phase, these can be accounted for so that intrinsic radiosensitivity values can be derived. Fig. 
1 shows the sequence of imaging sessions and treatment phases required for the analytical 
derivation of the radiobiological parameters in this case.  
From Eq. (5) it can be shown that if we consider only the first phase of treatment,  








=∆−








+ ]1[
]0[
]1[
]1[
2]1[]1[
]1[]1[ ln
i
iii
ii N
N
tf
DBDA γβα       (7) 
Similar equations hold for phase 2 and phase 3, giving us the following set of relationships 
between α, β and γ, and the surviving clonogen number following each phase: 
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This set of equations can be solved voxel by voxel, provided the determinant of the 33×  
matrix is non-zero. In practice this means that no two treatment phases can have both the 
same dose per fraction and the same overall time per fraction. Note that if tumor repopulation 
is known to be negligible, γ can be set to zero and a two-phase treatment would then give 
sufficient information to solve for α and β.  
II.D. Optimizing the Dose Distribution 
Having derived patient-specific radiobiological parameters, the most recent set of 
clonogen density and oxygenation images can then be used to optimize the dose distribution 
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for a final phase of treatment. There are a number of possible approaches to the dose 
optimization problem, here we have used a method to maximize the overall TCP for a fixed 
integral dose, similar to that used by Yang and Xing.19 Details of the method are given in the 
Appendix.  
II.E. Tumor Model 
The technical feasibility of the methods described above is demonstrated by 
application to a model tumor. The tumor is spherical with a core of bulk disease of uniform 
clonogen density surrounded by a region of tumor spread in which clonogen density drops 
exponentially with distance from the core.43 With a core clonogen density ρmax, core radius RC 
and overall tumor radius RT, the clonogen density varies with radius r as shown in Eq. (9).  
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Uniform intrinsic values of α, β and γ are specified for the whole tumor. The oxygen 
dependence takes the form suggested by Wouters and Brown,41 such that: 
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where pi is the partial pressure of oxygen in voxel i, 
maxα
OER  and 
maxβOER are maximum 
oxygen enhancement ratios for α and β respectively, and Km is the oxygen partial pressure at 
which half-maximum sensitization occurs. The partial pressure of oxygen takes a uniform 
value pmax outside the core, and drops exponentially to a minimum value pmin at the centre of 
the core:  
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The resulting radial profiles for clonogen density and partial pressure of oxygen are shown in 
Fig. 2. Maximum and minimum oxygen pressures can be chosen independently for each 
imaging session and where temporal variations in oxygenation occur, it is assumed that the 
average of the pre- and post-treatment hypoxia images for each phase represents a good 
approximation to the effective oxygenation during that treatment phase. For simplicity, the 
proliferation rate has been chosen to be spatially invariant. However, spatial variations in γ as 
a function of oxygenation could easily be incorporated provided the form of the oxygen 
dependence was known, although the literature is somewhat inconsistent on this point.44,45 We 
have used the values of 
maxα
OER , 
maxβOER  and Km proposed by Wouters and Brown
41
 
throughout and results are presented for a range of literature-derived values for ρmax, α, β, γ, 
RC, RT, pmax and pmin.  
III. RESULTS  
III.A. Importance of Radiobiological Parameters 
For spatially varying dose prescriptions to be a viable proposition, the required level 
of dose inhomogeneity must be both clinically significant and clinically achievable. To 
investigate the sensitivity of prescribed voxel dose to variations in α, β, γ and ρ, a model 
tumor with a volume of 100cm3 and with a set of literature-derived radiobiological parameters 
typical of prostate cancer27 was considered. These parameters are listed in TABLE I. The 
voxel dose required to maximize total TCP subject to fixed integral dose was calculated in the 
case where the reference voxel (i.e. a voxel in which all parameters take the reference values) 
receives 78Gy, with the integral dose equal to that for a uniform irradiation to 78Gy in 39 
fractions.  
Fig. 3 shows the effect on voxel dose of varying each of α, β, γ and ρ over a clinically 
relevant range,46 normalized to the reference voxel dose, with all other parameters fixed. It 
can be seen that the prescribed dose is relatively insensitive to variations in clonogen density, 
with wide variations in clonogen number resulting in modest alterations in voxel dose. 
Similarly, prescribed dose does not change dramatically with proliferation rate, except for 
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very rapidly proliferating tumors. However, changes in β and particularly α lead to significant 
changes in dose within a clinically realistic range. The importance of using patient-specific 
radiosensitivity can be seen by considering typical quoted values of population variance in α 
in the light of Fig. 3. Nahum et al.27 quote a standard error of σα=0.06 Gy-1 for prostate 
cancers. Variations in α of +/- σα would correspond to changes of prescribed dose of -13% or 
+17% respectively for this parameter set.  
III.B. Method I: Numerical Optimization of Patient-Specific Radiobiological Parameters 
The numerical optimization method was tested by using the model tumor described 
above to generate observed post-treatment clonogen density images based on an assigned set 
of radiobiological parameters. Expected clonogen maps based on an initial estimated set of 
parameters were generated in the same manner. The estimated values were then iteratively 
optimized to minimize the objective function described in Eq. (6). However, fundamental 
limitations of this method quickly became apparent, even when dealing with well-behaved 
modelled data.  
 If we consider only a single voxel within the modelled tumor, the objective function 
is given by: 
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where α, β and γ are actual values and αest, βest and γest are estimated values.  
This function becomes zero when  
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This condition can be satisfied by numerous combinations of αest, βest and γest, so in this case 
the problem is degenerate. Now consider the whole tumor for a case in which phase 1 consists 
of a uniform irradiation of a tumor with uniform oxygenation. Each voxel contributes a term 
of the form given in Eq. (12) to the objective function, with each term simply scaled by the 
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initial clonogen number in that voxel. If the condition in Eq. (13) is met, then each term will 
be zero, so the problem remains degenerate.  
 If the phase 1 dose is non-uniform, each voxel has a different value of D[1], so Eq. 
(13) now represents a set of conditions, each of which must be satisfied in order to find the 
optimal α, β and γ. This breaks the degeneracy of the problem and results in a single global 
minimum of the OF, but a large number of local minima remain and the global minimum is 
extremely narrow, as illustrated in Fig. 4. The optimization process will therefore either be 
extremely time-consuming or prone to significant errors, even when considering perfect data.  
 If random noise is introduced into the modelled image data, the depth of the global 
minimum in the OF is reduced to a much greater extent than that of the local minima. This 
effect becomes more prominent as the signal-to-noise ratio (SNR) is reduced and by the time 
random noise represents just a few percent of the image signal the global minimum is 
indistinguishable from the local minima. In practice, for any realistic set of clinical images, 
the problem will once more become effectively degenerate and the optimization process is 
unlikely to yield reliable, clinically relevant results. We therefore turn our attention to the 
analytical approach to deriving α, β and γ.  
III.C. Method II: Analytical Derivation of Patient-Specific Radiobiological Parameters 
III.C.1. Sensitivity to Image Noise 
When applied to noise-free modelled data in which clonogen density images perfectly 
represent a tumor for which the linear-quadratic model is an exact fit, this method returns the 
correct values of α, β and γ for each voxel. In order to assess the sensitivity of the solutions to 
image noise, random fluctuations were introduced into the modelled image sets and the errors 
in calculated parameters assessed. In each case a maximum noise amplitude aN was set as a 
percentage of voxel signal, and the true voxel value multiplied by a factor 1+vN where vN  was 
randomly selected with uniform probability in the range –aN to +aN for each voxel. Noise was 
randomly introduced in this way to each of the 4 clonogen density maps. The tumor model 
incorporated a standard set of parameter values representative of prostate cancer27 and a fixed 
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treatment regime for phases 1 to 3 was used, as shown in TABLE I. The model tumor was 
fully oxygenated throughout. The noise amplitude was varied between 0% and 100%, the 
simulation was run 10 times for each noise level and both the mean value and the standard 
deviation (SD) over the tumor for each parameter (α, β and γ) was recorded on each occasion. 
Fig. 5 shows the root mean square (RMS) of the error in the mean value and the average SD 
for each noise level for α, β and γ. The RMS error indicates the accuracy with which the 
mean voxel value represents the true value of a parameter, whilst the SD of the voxel values is 
representative of the stability of calculation results for individual voxels, given that the tumor 
model has uniform intrinsic radiosensitivity and proliferation. It is clear that for α and β, the 
mean value is much more stable than the individual voxel values with increasing noise, 
suggesting that for a realistic signal-to-noise ratio (SNR) it may be necessary to average the 
radiosensitivity values over the target. For a noise level of 10%, the RMS errors of mean 
values of α, β and γ are 1.1%, 3.1% and 9.2% respectively. When applied to the model 
outlined in the previous section, these errors combine to give an uncertainty in voxel dose of 
approximately 1%.  
III.C.2. Effect of Treatment Parameters 
It should be noted that the sensitivity to noise of the parameter calculation will vary 
depending on the treatment parameters (D, f  and ∆t) chosen for the initial treatment phases. 
For perfect modelled data, the determinant of the 33×  matrix in Eq. (8) need only be non-
zero. In general however, increasing the magnitude of the determinant will reduce the effect 
of noise on the calculation so it would be desirable to maximize the determinant subject to 
practical or clinical constraints.  
To illustrate the effect of the various parameters on the determinant and consequently 
on the errors in calculated radiosensitivity and proliferation rate, we consider two specific 
scenarios. First, consider a situation in which phase 1 and phase 2 are both delivered at 2Gy 
per fraction. Phase 1 consists of 10 fractions delivered over 12 days (e.g. daily on weekdays 
only), whilst phase 2 consists of 5 fractions delivered over 5 days. Supposing we then wish to 
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deliver phase 3 in a single fraction, Fig. 6(a) illustrates the dependence of the determinant 
upon the size of this fraction. The noise sensitivity analysis described in the previous section 
was repeated using a 10% noise level and standard tumor model as outlined in TABLE I for a 
range of determinant values attained by adjusting the phase 3 fraction size, with the results 
presented in Fig. 6(b). It can be seen that for large values of the determinant, errors in the 
mean calculated α and β approach approximately 0.3%, and that errors of both parameters are 
stable and below 1% when the magnitude of the determinant is greater than 100, 
corresponding to a phase 3 dose of approximately 3.5Gy. It should be noted, however, that if 
D[3] is fixed then the determinant increases linearly with f[3], so a determinant of -100 could 
equally be achieved if phase 3 consisted of 4 fractions each of 2.5Gy. Fig. 6(b) also shows 
that errors in calculated γ are unaffected when the determinant is increased in this way, since 
the overall treatment time is not being changed so the ability to distinguish between different 
proliferation rates is not improved despite the increase in the determinant.  
Secondly, we consider the effect of varying the overall treatment time for phase 1, 
with all other parameters fixed. In this case we have chosen phase 3 to consist of 3 fractions 
each of 2.5Gy delivered over 3 days, with all other parameters as in the previous example. 
The dependence of the determinant on ∆t[1] and the consequent errors in computed parameters 
are shown in Fig. 6(c) and 6(d). In this case it can be seen that increasing the determinant in 
this way reduces errors in α, β and γ. It is therefore clear that uncertainties in α, β and γ 
depend not only on the magnitude of the determinant, but also on the means of increasing the 
determinant, so the relative importance of errors in these 3 parameters must be considered 
when designing the initial treatment phases.  
III.D. Optimization of Final Phase Dose Distribution 
Clonogen density and hypoxia data was generated for 4 different model tumors 
(without added noise), and in each case the radiobiological parameters were derived and the 
dose distribution giving the maximum TCP was generated. Models T1 and T2 use 
radiobiological parameters typical of a prostate tumor, whilst T3 and T4 represent a 
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glioblastoma or high-grade astrocytoma.22 T1 is well oxygenated, whilst T2 has reduced 
oxygenation in the core throughout the course of treatment. Similarly, T3 contains a core 
which remains mildly hypoxic throughout treatment, whilst the core of T4 is initially hypoxic, 
but is allowed to reoxygenate during the course of treatment. Details of the parameters used 
for each model are given in TABLE II, which also includes both the TCP values for uniform 
irradiation and the maximum achievable TCP for the same integral dose. In each case the 
correct α, β and γ values were derived. Fig. 7 shows the initial clonogen density and hypoxia 
maps, and the optimized final phase dose distribution through the centre of the tumor for each 
model.  
 The results for T1 indicate that for a well oxygenated prostate tumor, uniform 
irradiation gives a high probability of local control and there is relatively little benefit from 
redistributing dose purely to account for variations in clonogen density. However, when a 
persistently hypoxic region is introduced in T2, the TCP for the conventional treatment drops 
dramatically, indicating a probable failure of local control, whilst the redistribution of dose 
allows a TCP close to 1 to be achieved. The maximum final phase voxel dose for T2 was 
106.2Gy, representing an increase by a factor of nearly 2.7 compared with the uniform final 
phase dose of 40Gy, whilst for T1 the maximum voxel dose was 62.7Gy.  
 T3 also suggests that hypoxia can limit the TCP for a conventional treatment, and that 
redistribution of dose could lead to significant increases in TCP. The maximum voxel dose of 
68Gy represents an increase by a factor of 2.1 compared with the uniform final phase dose of 
32Gy. T4 highlights the importance of imaging hypoxia more than once during the course of 
treatment. Initially, this tumor appears to have a poorer prognosis than T3, since it contains 
more clonogens and has a larger hypoxic region with lower relative oxygenation. However, 
the hypoxia in this case does not persist through the course of treatment, and consequently the 
TCP for the conventional uniform dose treatment is higher than for T3 and the gain in TCP 
due to redistribution of dose is more modest, as is the increase in maximum voxel dose to 
54.9Gy.  
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IV. DISCUSSION 
We have presented a theoretical framework for optimizing radiotherapy based on 
patient-specific radiobiological parameters derived from a series of functional images. This 
method has been illustrated by application to a specific radiobiological model and different 
strategies for acquiring the necessary parameters have been investigated. The basic approach, 
however, is independent of the precise form of the chosen model and could be used to assess 
the validity of a range of models in a clinical setting.  
Of the two approaches discussed for deriving the radiosensitivity parameters, the 
optimization of the parameter set based on a minimal set of radiation response information is 
logistically the more attractive, for a number of reasons. Firstly, it would require only two 
imaging sessions, and secondly only a single phase of treatment would be needed to derive 
the parameters, and this phase may form part of a conventionally prescribed treatment using a 
standard fractionation. However, in the case of the linear-quadratic model the optimization 
problem becomes effectively degenerate in the presence of image noise, and this technique is 
unlikely to prove practicable in a clinical setting. The analytical derivation based on multiple 
test phases may be logistically more difficult to implement as it requires numerous imaging 
sessions, relies on the careful co-ordination of treatment and imaging schedules, and 
necessitates deviations from conventional fractionations in order to produce the necessary 
information. However, this approach proves to be surprisingly robust to image noise, and the 
required variations in fractionation appear to be relatively modest. It also appears that 
adequate variations in overall treatment time between test phases may be achievable simply 
through judicious scheduling to make use of natural breaks in treatment (e.g. weekends). 
Overall, the analysis we have presented suggests that the application of this technique may be 
feasible using a clinically acceptable schedule of test treatments.  
In general, the number of imaging sessions required will depend on the complexity of 
the radiobiological model and will increase linearly with the number of independent 
parameters in the model. The basic methodology is sufficiently flexible to allow changes in 
the fundamental form of the model, or simply the extension of the model to include additional 
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factors or phenomena: the model could be extended such that hypoxic regions contain a 
mixture of active, quiescent and necrotic cells, with quiescent cells becoming active with 
reoxygenation; the bystander effect could be modelled so that the TCP in one voxel depends 
on the dose in neighbouring voxels; temporal variations in proliferation rate, if sufficiently 
well understood, could be incorporated into the model. Conversely, if any of the parameters 
can be reliably determined prior to treatment (e.g. estimating proliferation rate using magnetic 
resonance spectroscopy, or a priori knowledge that the proliferation rate is negligible), fewer 
images will be needed to solve for the remaining free parameters.  
 Parametric sensitivity analysis and the application of the tuned radiobiolical model to 
a number of modelled test cases showed that the dominant factor necessitating the 
redistribution of dose within a tumor was the reduction of radiosensitivity due to local 
hypoxia. The examples chosen indicate that where significant hypoxia exists, redistributing 
dose can lead to a substantial increase in TCP, and suggest that hypoxia may be the most 
significant factor in limiting local control rates for conventional treatments. This is in good 
agreement with other similar work.19,20,42 Even in the absence of hypoxia, if a relatively large 
volume of the target contains a low density of clonogens the redistribution of dose may allow 
a small but worthwhile increase in TCP and may also benefit organs at risk peripheral to the 
target. It should be noted that the optimized dose distributions presented here represent an 
ideal prescribed dose distribution over the tumor and take no account of organs at risk, or the 
clinical acceptability of the changes in fractionation due to dose redistribution. In practice, a 
final treatment plan would need to be optimized considering normal tissue dose constraints 
and limitations in the physical delivery of treatment in addition to the ideal prescribed 
distribution, and in many cases the ideal distribution may not prove clinically deliverable. 
However, the magnitude of the potential increases in TCP shown for hypoxic tumors suggests 
that even in cases where only a limited redistribution of dose was possible, substantial 
increases in TCP may be achievable within sensible clinical constraints.  
 Potentially the most serious limitation of our current model is the implicit assumption 
that cell death occurs effectively instantaneously following irradiation. This is clearly not the 
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case, and there are two obvious approaches to solving this problem. The first would be to 
adapt the schedules to allow several cell cycles between each treatment phase and the 
subsequent imaging session, allowing the majority of cell damage to be fully expressed. This 
would be less than ideal for rapidly proliferating tumors as it would result in prolonging the 
overall treatment. The second alternative would be to incorporate the time-dependence of the 
progression from cell damage to cell death into the radiobiological model, requiring a more 
thorough understanding of this process than is currently available in the literature. However, 
recent work by Yang et al. 47 suggests that early evaluation of the response of tumors to 
irradiation may be possible by developing markers to image early changes in cellular 
behaviour, such as proliferation, which correlate well with eventual cell survival.  
 The model we have presented is limited by the availability of suitable imaging, 
radiobiological assumptions and clinical practicality, and the development and assessment of 
suitable parametric imaging techniques remains paramount. However, even given sizeable 
uncertainties in parametric data we have demonstrated significant potential gains, showing 
how this kind of technique could unlock the true potential of IMRT and functional imaging. It 
should also be noted that it would not be necessary to use clinically derived radiobiological 
parameters immediately to prescribe non-uniform dose distributions: in the first instance the 
technique could be used to simply calculate radiosensitivity and use the calculated parameters 
to predict TCP for a conventional final phase of treatment. From Eq. (8) it is clear that the 
calculation of α, β and γ does not depend on absolute clonogen densities, but only on the 
ratios of pre- and post-treatment clonogen numbers. In order to simply calculate the model 
parameters we do not therefore need to be able to absolutely quantify clonogenic cell density, 
we simply need images from which relative tumor burden can be derived. Using the method 
in this manner would provide a means of testing the predictions of a radiobiological model in 
a clinical setting prior to the application of the model for dose prescription.  
V. CONCLUSION 
We have considered the question of how emerging functional imaging techniques 
may be used to inform the planning of radiotherapy treatments and proposed a formalism for 
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using functional imaging both to determine patient-specific radiobiological properties and to 
prescribe an optimal non-uniform dose distribution based on these parameters. The feasibility 
of this approach has been demonstrated by application to a specific radiobiological model. 
The development and validation of techniques for quantitative imaging of both tumor burden 
and hypoxia would pave the way for clinical trials to assess the validity of current models for 
predicting tumor response. This in turn would allow the technique to be used to prescribe 
optimal dose distributions for individual patients. Results show potential for significant 
improvements in tumor control over a range of realistic parameters and assumptions.  
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TABLE I. Standard parameter set.  
Radiobiological Parameters Treatment Parameters 
α [ Gy-1] 0.26 Phase 1 
D[1] [Gy] 20 
β [ Gy-2] 0.0312 f[1] [#] 10 
∆t[1] [days] 12 
γ [ day-1] 0.0173 Phase 2 
D[2] [Gy] 10 
ρmax [cells cm-3] 107 f[2] [#] 5 
∆t[2] [days] 5 
maxα
OER  2.5 Phase 3 
maxβOER  3.0 D
[3]
 [Gy] 7.5 
Κm [mm Hg] 3.28 f[3] [#] 3 
∆t[3] [days] 3 
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TABLE II. Parameters for tumor models T1-T4.  
Parameter T1 T2 T3 T4 
ρmax [cells cm-3] 5x106 5x106 1x107 1x107 
α [Gy-1] 0.26 0.26 0.31 0.31 
β [Gy-2] 0.0312 0.0312 0.06 0.06 
γ [day-1] 0.0173 0.0173 0.1155 0.1155 
Core radius [cm] 2.0 2.0 0.8 1.2 
Tumor radius [cm] 4.0 4.0 4.0 4.8 
Total clonogens 2.1 x 108 2.1 x 108 5.5 x 107 1.5 x 108 
Initial Min pO2  
[mm Hg] 
20 2 5 1 
Initial Max pO2 
[mm Hg] 
50 50 50 50 
Phase: [1] [2] [3] [1] [2] [3] [1] [2] [3] [1] [2] [3] 
D [Gy] 20 10 7.5 20 10 7.5 10 10 7.5 10 10 7.5 
f [#] 10 5 3 10 5 3 5 5 3 5 5 3 
∆t [days] 12 5 3 12 5 3 7 5 3 7 5 3 
Min pO2 [mm Hg] 20 20 20 2 2 2 5 5 5 5 10 20 
Max pO2 [mm Hg] 50 50 50 50 50 50 50 50 50 50 50 50 
D[4] [Gy] 40 40 32 32 
F[4] [#] 20 20 16 16 
∆t[4] [days] 26 26 22 22 
Dtotal [Gy]  
(2Gy/# equiv.) 
78 78 60 60 
Unif. Dose TCP 0.9698 0.2340 0.3691 0.5832 
Max TCP 0.9999 0.9998 0.9996 0.9991 
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FIG. 1. Sequence of imaging sessions and treatment phases for the analytical derivation of 
radiobiological parameters.  
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FIG. 2. Radial profile of clonogen density and partial pressure of oxygen within the spherical 
model tumor.  
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 FIG. 3. Sensitivity of the dose prescription for a particular voxel to variations in the value of 
(a) effective α ; (b) effective β ; (c) proliferation rate γ (potential doubling times of 1, 10, 100 
and 1000 days are labelled); (d) clonogen density ρ. Doses are normalized to a reference 
voxel with the parameter values given in TABLE I.  
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 FIG. 4. Local and global minima of the objective function (OF) in the α-β optimization 
plane.  
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FIG. 5. Effect of increasing image noise on derived radiobiological parameters. Solid lines 
show the RMS error in the mean computed value, dashed lines indicate the standard deviation 
of individual voxel values.  
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FIG. 6. (a) The effect on the matrix determinant of varying the phase 3 fraction size; (b) 
shows how uncertainties in calculating α, β and γ vary as the determinant is varied in this 
manner; (c) shows how the matrix determinant varies with phase 1 treatment time; (d) shows 
the subsequent effect on uncertainties in calculated parameters. (For (b) and (d), solid lines 
show the RMS error in the mean computed value, dashed lines indicate the standard deviation 
of individual voxel values).  
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FIG. 7. Initial parametric maps and final dose distributions for 4 tumor models. The 
parameters assigned to each model are given in TABLE II.  
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APPENDIX 
The Lagrange multiplier method can be used to maximize TCP as follows:  
For fixed integral target dose Et,  
ti
i
i EDm =∑           (A.1) 
where mi is the mass of the ith voxel.  
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where Dref is the reference dose to a voxel with reference values of the radiobiological 
parameters (ρref, αref, βref and γref) resulting in a TCP of TCPref within this voxel.  
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We can solve Eq. (A.12) numerically for iZ using Newton’s method, and hence derive 
desired voxel doses as follows:  
1) Set Dref to an initial estimated value. We have used the uniform final phase dose Dunif.  
2) Set initi ZZ = , calculated using an initial estimate of the optimal dose distribution. 
Here we have chosen to use 
maxρ
ρi
refi DD ⋅=   
3) Repeating the following steps (a. to e.) converges to a solution for Zi within a few 
iterations: 
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4) Eq. (A.10) can then be rearranged to find Di.  
5) Calculate the resultant sum of voxel doses ∑=
i
iDS  and compare with the intended 
value unifDnS ⋅=int  
6) Set 
S
SDD refref int⋅→  
The iteration of steps 1) to 6) rapidly converges to a solution for the optimal dose distribution.  
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